ANIP Q2 2019 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$54M+15.0% YoY

Gross Profit

$39M71.2% margin

Operating Income

$9M17.1% margin

Net Income

$6M11.9% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$786,000

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$447M

Total Liabilities

$239M

Stockholders' Equity

$208M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$47M	+15.0%
Gross Profit	$39M	$31M	+26.2%
Operating Income	$9M	$7M	+27.9%
Net Income	$6M	$3M	+135.6%

Revenue Segments

Sales Of Generic Pharmaceutical Products

$36M64%

Sales Of Branded Pharmaceutical Products

$14M25%

Sales Of Contract Manufactured Products

$6M10%

Product Development Services

$411,0001%

Other Revenues

$259,0000%

Geographic Segments

United States

$52M96%

Canada

$2M4%